Skip to main content
Top
Published in: Journal of Gastroenterology 3/2014

01-03-2014 | Original Article—Liver, Pancreas, and Biliary Tract

Pancreatic involvement in Japanese patients with von Hippel-Lindau disease: results of a nationwide survey

Authors: Hisato Igarashi, Tetsuhide Ito, Isao Nishimori, Kenji Tamura, Ichiro Yamasaki, Masao Tanaka, Taro Shuin

Published in: Journal of Gastroenterology | Issue 3/2014

Login to get access

Abstract

Background

The frequency and prognosis of pancreatic endocrine tumors (PNET)/pancreatic cystic tumors (PCT) in Japanese patients with von Hippel-Lindau disease (VHL) are still open to question.

Methods

We conducted the first nationwide epidemiological study of VHL disease in Japan to elucidate this question. Data on 377 VHL patients (PNET, 53; PCT, 152) were reported, and then their clinical characteristics were analyzed.

Results

PNET was found in 14.1 % and PCT in 40.3 %; 4.5 % had both. The onset of PNET and PCT mostly occurred at 30–39 years of age (median ages, 34 and 33 years, respectively). Metastasis was observed in 7.5 % of PNET patients at diagnosis, and 64.2 % underwent surgery including enucleation, partial and total pancreatectomy, and bypass surgery. Two patients received non-surgical therapies. No PNET-related deaths were observed. In PCT patients, no metastasis was observed at diagnosis, and 9.2 % underwent surgery or drainage. According to the classification system without or with adrenal pheochromocytoma, the VHL patients studied herein were subdivided into 313 (83 %) with VHL type 1 and 64 (17 %) with VHL type 2; 29 (9.3 %) and 24 (37.5 %) patients had PNET with VHL type 1 and 2, suggesting that patients with VHL type 2 were significantly more related to PNET than those with VHL type 1 (P < 0.01).

Conclusions

This study showed no significant difference in the epidemiology of pancreatic involvement between Japanese and non-Japanese VHL patients. Concerning the prognosis, follow-up study is needed.
Literature
1.
go back to reference Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993;260:1317–20.PubMedCrossRef Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993;260:1317–20.PubMedCrossRef
2.
go back to reference Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, et al. von Hippel-Lindau disease. Lancet. 2003;361:2059–67.PubMedCrossRef Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, et al. von Hippel-Lindau disease. Lancet. 2003;361:2059–67.PubMedCrossRef
3.
4.
5.
go back to reference Hough DM, Stephens DH, Johnson CD, Binkovitz LA. Pancreatic lesions in von Hippel-Lindau disease: prevalence, clinical significance, and CT findings. Am J Roentgenol. 1994;162:1091–4.CrossRef Hough DM, Stephens DH, Johnson CD, Binkovitz LA. Pancreatic lesions in von Hippel-Lindau disease: prevalence, clinical significance, and CT findings. Am J Roentgenol. 1994;162:1091–4.CrossRef
6.
go back to reference Hammel PR, Vilgrain V, Terris B, Penfomis A, Sauvanet A, Correas JM, et al. Pancreatic involvement in von Hippel-Lindau disease. The Groupe Francophone d’Etude de la Maladie de von Hippel–Lindau. Gastroenterology. 2000;119:1087–95.PubMedCrossRef Hammel PR, Vilgrain V, Terris B, Penfomis A, Sauvanet A, Correas JM, et al. Pancreatic involvement in von Hippel-Lindau disease. The Groupe Francophone d’Etude de la Maladie de von Hippel–Lindau. Gastroenterology. 2000;119:1087–95.PubMedCrossRef
7.
go back to reference Neumann HP, Dinkel E, Brambs H, Wimmer B, Friedburg H, Volk B, et al. Pancreatic lesions in the von Hippel-Lindau syndrome. Gastroenterology. 1991;101:465–71.PubMed Neumann HP, Dinkel E, Brambs H, Wimmer B, Friedburg H, Volk B, et al. Pancreatic lesions in the von Hippel-Lindau syndrome. Gastroenterology. 1991;101:465–71.PubMed
8.
go back to reference Kanno A, Satoh K, Hamada S, Hirota M, Masamune A, Motoi F, et al. Serous cystic neoplasm of the whole pancreas in a patient with von Hippel-Lindau disease. Intern Med. 2011;50:1293–8.PubMedCrossRef Kanno A, Satoh K, Hamada S, Hirota M, Masamune A, Motoi F, et al. Serous cystic neoplasm of the whole pancreas in a patient with von Hippel-Lindau disease. Intern Med. 2011;50:1293–8.PubMedCrossRef
9.
go back to reference Binkovitz LA, Johnson CD, Stephens DH. Islet cell tumors in von Hippel-Lindau disease: increased prevalence and relationship to the multiple endocrine neoplasms. Am J Roentgenol. 1990;155:501–5.CrossRef Binkovitz LA, Johnson CD, Stephens DH. Islet cell tumors in von Hippel-Lindau disease: increased prevalence and relationship to the multiple endocrine neoplasms. Am J Roentgenol. 1990;155:501–5.CrossRef
10.
go back to reference Charlesworth M, Verbeke CS, Falk GA, Walsh M, Smith AM, Morris-Stiff G. Pancreatic lesions in von Hippel-Lindau disease? A systemic review and meta-synthesis of the literature. J Gastrointest Surg. 2012;16:1422–8. Charlesworth M, Verbeke CS, Falk GA, Walsh M, Smith AM, Morris-Stiff G. Pancreatic lesions in von Hippel-Lindau disease? A systemic review and meta-synthesis of the literature. J Gastrointest Surg. 2012;16:1422–8.
11.
go back to reference Tamura K, Nishimori I, Ito T, Yamasaki I, Igarashi H, Shuin T. Diagnosis and management of pancreatic tumor in von Hippel-Lindau disease. World J Gastroenterol. 2010;16:4515–8.PubMedCentralPubMedCrossRef Tamura K, Nishimori I, Ito T, Yamasaki I, Igarashi H, Shuin T. Diagnosis and management of pancreatic tumor in von Hippel-Lindau disease. World J Gastroenterol. 2010;16:4515–8.PubMedCentralPubMedCrossRef
12.
go back to reference Yamasaki I, Nishimori I, Ashida S, Kohsaki T, Onishi S, Shuin T. Clinical characteristics of pancreatic neuroendocrine tumors in Japanese patients with von Hippel-Lindau disease. Pancreas. 2006;33:382–5.PubMedCrossRef Yamasaki I, Nishimori I, Ashida S, Kohsaki T, Onishi S, Shuin T. Clinical characteristics of pancreatic neuroendocrine tumors in Japanese patients with von Hippel-Lindau disease. Pancreas. 2006;33:382–5.PubMedCrossRef
13.
go back to reference Cheng TY, Su CH, Shyr YM, Lui WY. Management of pancreatic lesions in von Hippel-Lindau disease. World J Surg. 1997;21:301–12.CrossRef Cheng TY, Su CH, Shyr YM, Lui WY. Management of pancreatic lesions in von Hippel-Lindau disease. World J Surg. 1997;21:301–12.CrossRef
14.
go back to reference Libutti SK, Choyke PL, Bartlett DL, Vargas H, Walther M, Lubensky I, et al. Pancreatic neuroendocrine tumors associated with von Hippel-Lindau disease: diagnostic and management recommendations. Surgery. 1998;124:1153–9.PubMedCrossRef Libutti SK, Choyke PL, Bartlett DL, Vargas H, Walther M, Lubensky I, et al. Pancreatic neuroendocrine tumors associated with von Hippel-Lindau disease: diagnostic and management recommendations. Surgery. 1998;124:1153–9.PubMedCrossRef
15.
go back to reference Libutti SK, Choyke PL, Alexander HR, Glenn G, Bartlett DL, Zbar B, et al. Clinical and genetic analysis of patients with pancreatic neuroendocrine tumors associated with von Hippel-Lindau disease. Surgery. 2000;128:1022–7. Discussion 1027–8.PubMedCrossRef Libutti SK, Choyke PL, Alexander HR, Glenn G, Bartlett DL, Zbar B, et al. Clinical and genetic analysis of patients with pancreatic neuroendocrine tumors associated with von Hippel-Lindau disease. Surgery. 2000;128:1022–7. Discussion 1027–8.PubMedCrossRef
16.
go back to reference Mukhopadhyay B, Sahdev A, Monson JP, Besser GM, Reznek RH, Chew SL. Pancreatic lesions in von Hippel-Lindau disease. Clin Endocrinol (Oxf). 2002;57:603–8.CrossRef Mukhopadhyay B, Sahdev A, Monson JP, Besser GM, Reznek RH, Chew SL. Pancreatic lesions in von Hippel-Lindau disease. Clin Endocrinol (Oxf). 2002;57:603–8.CrossRef
17.
go back to reference Delman KA, Shapiro SE, Jonasch EW, Lee JE, Curley SA, Evans DB, et al. Abdominal visceral lesions in von Hippel-Lindau disease: incidence and clinical behavior of pancreatic and adrenal lesions at a single center. World J Surg. 2006;30:665–9.PubMedCrossRef Delman KA, Shapiro SE, Jonasch EW, Lee JE, Curley SA, Evans DB, et al. Abdominal visceral lesions in von Hippel-Lindau disease: incidence and clinical behavior of pancreatic and adrenal lesions at a single center. World J Surg. 2006;30:665–9.PubMedCrossRef
18.
go back to reference Blansfield JA, Choyke L, Morita SY, Choyke PL, Pingpank JF, Alexander HR, et al. Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Surgery. 2007;142:814–8. Discussion 818.e1–2. Blansfield JA, Choyke L, Morita SY, Choyke PL, Pingpank JF, Alexander HR, et al. Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Surgery. 2007;142:814–8. Discussion 818.e1–2.
19.
go back to reference Lee KH, Lee JS, Kim BJ, Lee JK, Kim SH, Kim SH, et al. Pancreatic involvement in Korean patients with von Hippel-Lindau disease. J Gastroenterol. 2009;44:447–52.PubMedCrossRef Lee KH, Lee JS, Kim BJ, Lee JK, Kim SH, Kim SH, et al. Pancreatic involvement in Korean patients with von Hippel-Lindau disease. J Gastroenterol. 2009;44:447–52.PubMedCrossRef
20.
go back to reference NCCN Clinical Practice Guidelines in Oncology (NCCN guidelines™). Neuroendocrine tumors, version I. 2011. NCCN.org. National Comprehensive Cancer Network, Inc. 2011. NCCN Clinical Practice Guidelines in Oncology (NCCN guidelines™). Neuroendocrine tumors, version I. 2011. NCCN.org. National Comprehensive Cancer Network, Inc. 2011.
22.
go back to reference Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72.PubMedCrossRef Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72.PubMedCrossRef
23.
go back to reference Ito T, Sasano H, Tanaka M, Osamura RY, Sasaki I, Kimura W, et al. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol. 2010;45:234–43.PubMedCrossRef Ito T, Sasano H, Tanaka M, Osamura RY, Sasaki I, Kimura W, et al. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol. 2010;45:234–43.PubMedCrossRef
24.
go back to reference Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514–23.PubMedCrossRef Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514–23.PubMedCrossRef
25.
go back to reference Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:501–13.PubMedCrossRef Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:501–13.PubMedCrossRef
Metadata
Title
Pancreatic involvement in Japanese patients with von Hippel-Lindau disease: results of a nationwide survey
Authors
Hisato Igarashi
Tetsuhide Ito
Isao Nishimori
Kenji Tamura
Ichiro Yamasaki
Masao Tanaka
Taro Shuin
Publication date
01-03-2014
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 3/2014
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-013-0794-1

Other articles of this Issue 3/2014

Journal of Gastroenterology 3/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.